Abstract
Improving cell uptake of metal compounds has became an important goal in the field of metal-based anticancer agents. This may combat platinum resistance and side effects seen commonly in current anticancer chemotherapy regimes. Here, we explore a novel degradable ruthenium-albumin hydrogel, which shows strong luminescence for cell imaging and high selectivity for cancer cells versus non-cancer cells. This is an early indication of the possibility of reducing unwanted side effects of metals by using bovine serum albumin hydrogel as a delivery strategy. This work provides a strong basis for development of a new class of metal-based cancer therapeutic agents.
Keywords:
Albumin; Hydrogel; Imaging; Ruthenium; Therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / toxicity
-
Cattle
-
Cell Line, Tumor
-
Coordination Complexes / chemistry
-
Coordination Complexes / pharmacology*
-
Coordination Complexes / toxicity
-
Endopeptidase K / chemistry
-
Humans
-
Hydrogels / chemical synthesis
-
Hydrogels / chemistry*
-
Hydrogels / toxicity
-
Luminescent Agents / chemical synthesis
-
Luminescent Agents / chemistry*
-
Luminescent Agents / toxicity
-
Lysosomes / metabolism
-
Microscopy, Confocal
-
Mitochondria / metabolism
-
Proteolysis
-
Ruthenium / chemistry*
-
Serum Albumin, Bovine / chemistry*
-
Serum Albumin, Bovine / toxicity
Substances
-
Antineoplastic Agents
-
Coordination Complexes
-
Hydrogels
-
Luminescent Agents
-
Serum Albumin, Bovine
-
Ruthenium
-
Endopeptidase K